Overview
Electromed Q1 FY 2026 revenue grows 15.1% yr/yr to $16.9 mln
Net income rises 44.9% to $2.1 mln, reflecting strong operational execution
Company authorized $10 mln stock repurchase in Q1
Outlook
Electromed expects manufacturing optimization to support future growth
Company anticipates CRM system to boost sales productivity
Electromed aims for attractive returns in fiscal 2026 and beyond
Result Drivers
SALES TEAM EXPANSION - Increase in direct sales representatives and higher net revenues per representative drove revenue growth
HOSPITAL AND DISTRIBUTOR GROWTH - Significant revenue growth in hospital and distributor markets contributed to overall revenue increase
OPERATIONAL EFFICIENCIES - Improved efficiencies and new CRM system enhanced sales productivity and profitability
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | $16.9 mln | ||
Q1 EPS | $0.25 | ||
Q1 Net Income | $2.1 mln | ||
Q1 Operating Income | $2.7 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Electromed Inc is $35.50, about 31.8% above its November 10 closing price of $24.20
Press Release: ID:nBw8lN4x1a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)